Physician profile
Jonathan T Swank
NPI 1750459228
$4,901.91
in general payments reported to CMS, 2019-2025
35 companies · $754 in 2025
The $754 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $785 · 2021: $623 · 2022: $474 · 2023: $579 · 2024: $684 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $543.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $414.91 | 2019-2023 | Xarelto |
| Pfizer INC. | $365.97 | 2019-2025 | |
| Lilly USA, LLC | $345.39 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $301.21 | 2020-2025 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.63 | 2019-2024 | Xifaxan |
| Amgen INC. | $208.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $204.28 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $158.82 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $156.20 | 2019-2025 | |
| Amarin Pharma, INC. | $140.67 | 2019-2022 | |
| Exact Sciences Corporation | $132.03 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $123.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.51 | 2019-2025 | Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $98.79 | 2019 | |
| Esperion Therapeutics, INC. | $92.84 | 2020-2023 | Nexletol |
| Abbott Laboratories | $64.69 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.21 | 2019 | |
| Vanda Pharmaceuticals INC. | $44.67 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.78 | 2020-2021 | |
| Eisai INC. | $28.52 | 2021-2022 | |
| Tactile Systems Technology INC | $27.28 | 2024 | Flexitouch Plus, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $25.53 | 2022 | |
| Csl Behring | $24.10 | 2025 | Hizentra |
| Phathom Pharmaceuticals, INC. | $18.80 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $17.19 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $16.62 | 2023 | Contrave |
| Daiichi Sankyo INC. | $15.85 | 2020 | |
| Astellas Pharma US INC | $15.77 | 2019 | |
| Antares Pharma, INC. | $15.68 | 2019 | |
| Medtronic, INC. | $14.29 | 2024 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $14.01 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $11.52 | 2021 | |
| Allergan, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Swank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.